Most lymphoid malignancies are associated with higher incidence and poorer prognosis in men than women. Epidemiological data associate reproductive hormones and oral contraceptives with reduced risk in women, attributed to estrogen. Estrogen's action is mediated by two nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), with different tissue distribution and actions. ERα promotes cell proliferation whereas ERβ shows anti-proliferative effects. Studies show ERβ to be predominantly expressed in lymphoid tissue. There is a dearth of studies about expression of ERβ in lymphoid malignancies. Hence, we characterized the expression of ERβ in low grade B-cell lymphomas by immunohistochemistry in men and women. Methods and Materials: Low-grade B-cell lymphomas diagnosed between 2006 and 2016 were retrieved from archives. ERβ immunostaining was performed on formalin-fixed paraffin-embedded sections of 45 lymphoma cases with typical histology, flow cytometry, and cytogenetics: 10 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (six men, four women), nine mantle cell lymphomas (five men, four women), 10 marginal zone lymphomas (four men, six women), eight follicular lymphomas (four men, four women), four classical (two men, two women), and four nodular lymphocyte predominant (two men, two women) Hodgkin lymphomas. Control tissue from tonsils, lymph nodes, and spleen were also immunostained. Results: Immunohistochemical ERβ staining of tonsils and lymph nodes in men and women show strong nuclear staining of lymphocytes in the germinal and mantle zone of the lymphoid follicles as compared to the paracortical region. The white pulp (periarteriolar lymphatic sheath) and red pulp in spleen show strong ERβ positivity. Strong nuclear staining of lymphocytes was seen in all cases of CLL/SLL, mantle, marginal, follicular, and Hodgkin
lymphomas. No difference in staining was seen between men and women in normal lymphoid and lymphoma specimens. Conclusion: All low-grade B-cell lymphomas strongly express ERβ in men and women, highlighting role of estrogens in pathogenesis. Since estrogen concentrations are higher in women, this might explain the sex predilection and poorer prognosis in men. Also, these results raise the possibility of using ERβ agonists as a novel therapeutic agent in these lymphomas.
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Cytogenetic Aberrations in Young Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Guanghong Liao, MD, Sujata Sajjan, MD, Tianyu Yang, MD, Silvat Sheikh-Fayyaz, MD, Nina Haghi, MD, Xinmin Zhang, Jing Wang, Brian Chen, Judith Brody, Kalpana Reddy, MD, Peihong Hsu, MD; Northwell Health, Great Neck, NY Objectives: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell hematologic malignancy with high global prevalence. Half the patients have somatic mutations, as demonstrated by fluorescence in situ hybridization (FISH) interphase analysis in over 80% of these cases. Del 11q22-23, TP53/17p deletion and del 6q are clinically significant high-risk prognostic factors. Few studies show that 10%-20% of patients are younger than 55 years, and their prognosis differs from older patients because of their longer survival. Methods: We retrospectively reviewed FISH studies in 800 patients with CLL/SLL diagnosed in our health system during years [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] . Results: A total of 120 patients (15%) are identified as younger than 55 years at first diagnosis with ages ranging from 31 to 55 (median age of 51). FISH results are available in 53 young patients and 167 older patients. Molecular aberrations found in the younger age group compared to older group are as follows: deletions at LAMP1/13q14 (35.8% vs 43.1%, P = .22), CEP12/trisomy 12 (26.4% vs 25.1%, P = .45), deletions of ATM/11q22-23 (16.9% vs 20.3%, P = .37), TP53/17p13 deletion (9.4% vs 17.9%, P = .1), and MYB/6q deletion (5.6% vs 4.8%, P = .55). Conclusion: Our study in younger patients demonstrates lower frequency of cytogenetic aberrations of 11q deletion and TP53/17p deletion, which are typically worse prognostic predictors of CLL/SLL. Although the changes are not statistically significant, this finding may contribute to the better outcomes of the younger patient group. More patients, additional data, and longer follow-up are necessary to determine the importance of these findings.
